Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
Cancers
|
October 23, 2021
Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
Sylvia Hartmann, Sonja Scharf, Yvonne Steiner, et al.
Hemasphere
|
July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
Moritz Bewarder, Maximilian Kiefer, Helene Will, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
Dominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Leukemia
|
June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting
Lorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.
Journal of Translational Autoimmunity
|
November 25, 2022
Autoantibodies against SUMO1-DHX35 in long-COVID
Lorenz Thurner, Natalie Fadle, Evi Regitz, et al.
Blood
|
January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome
Lorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.
Immunology Letters
|
September 12, 2024
Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis
Marie-Christin Hoffmann, Natalie Fadle, Evi Regitz, et al.
European Journal of Immunology
|
March 31, 2021
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients
Igor Kos, Benedikt Balensiefer, Vadim Lesan, et al.
The Lancet. Haematology
|
February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
Dominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
Molecular Cancer
|
September 28, 2024
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients
Sylvia Zöphel, Nadja Küchler, Johanna Jansky, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
Cancers
|
October 23, 2021
Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
Sylvia Hartmann, Sonja Scharf, Yvonne Steiner, et al.
Hemasphere
|
July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
Moritz Bewarder, Maximilian Kiefer, Helene Will, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
Dominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Leukemia
|
June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting
Lorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.
Journal of Translational Autoimmunity
|
November 25, 2022
Autoantibodies against SUMO1-DHX35 in long-COVID
Lorenz Thurner, Natalie Fadle, Evi Regitz, et al.
Blood
|
January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome
Lorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.
Immunology Letters
|
September 12, 2024
Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis
Marie-Christin Hoffmann, Natalie Fadle, Evi Regitz, et al.
European Journal of Immunology
|
March 31, 2021
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients
Igor Kos, Benedikt Balensiefer, Vadim Lesan, et al.
The Lancet. Haematology
|
February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
Dominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
Molecular Cancer
|
September 28, 2024
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients
Sylvia Zöphel, Nadja Küchler, Johanna Jansky, et al.
Page
of 7